NYSE$EW

Edwards Lifesciences Corp · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

Edwards Lifesciences reported Q3 2025, revenue of $1.55B, net income of $291.1M, diluted EPS of $0.50.

For Q3 2025, Edwards Lifesciences reported revenue of $1.55B, net income of $291.1M, diluted EPS was $0.50. Management discusses segment trends, capital allocation, and macro risks in the quarterly filing.

  • Revenue $1.55B.
  • Net income $291.1M.
  • Diluted EPS $0.50.
  • Edwards Lifesciences MD&A highlights operating priorities and liquidity.
  • Segment and geographic mix shape year-over-year comparisons.

Headline financials

Total Revenue

$1.55B

Previous: $1.35B+14.7%
EPS (adj)

$0.50

Previous: $5.13-90.3%
Gross Profit Margin

77.8%

Previous: 80.6%-3.5%
SG&A Expenses

514600000.0%

No prior period
R&D Expenses

280700000.0%

No prior period
Operating Profit Margin

19.8%

Previous: 25.9%-23.6%
Capital Expenditures

-$163M

Previous: -$203M+19.6%
Free Cash Flow

$128M

Previous: $2.87B-95.5%
Net Income

$291M

Previous: $3.07B-90.5%
Operating Income

$307M

Previous: $351M-12.4%
Gross Profit

$1.21B

Previous: $1.09B+10.7%
Cash & Equivalents

$2.69B

Previous: $3.68B-27.0%
Total Assets

$13.3B

Previous: $13B+2.3%

Revenue & EPS history

Edwards Lifesciences · Revenue · Quarterly

$1.55B

Q3 2025+14.7%vs Q3 2024
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Edwards Lifesciences · $1.26B total across 3 segments · Q3 2023

  • Transcatheter Aortic Valve Replacement
    $961M+11.4%
  • Surgical Structural Heart
    $247M+12.2%
  • Transcatheter Mitral & Tricuspid
    $52.4M+76.4%

Forward guidance

The quarterly filing discusses operating priorities, capital returns, and sector risks.

Tailwinds

  • MD&A highlights liquidity, capital, and core business trends.
  • Segment commentary supports the earnings narrative.

Headwinds

  • Macro, rates, or input costs may pressure near-term margins.
  • One-time items can affect year-over-year comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-1.3%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-1.5%

Avg return

30 days after

50%

35 / 70 earnings

Positive

+11.6%

Q1 2017

Best reaction

-31.4%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+1.9%+7.7%
Q4 2025+3.0%-1.5%+6.2%
Q3 2025-0.8%-0.8%+3.8%
Q2 2025+0.1%+4.1%-0.8%
Q1 2025+6.6%+8.3%+6.4%
Q4 2024+6.9%+7.4%-2.3%
Q3 2024-1.7%-1.8%-0.2%
Q2 2024-31.4%-26.8%-18.6%
Q1 2024-2.5%-4.4%-0.7%
Q4 2023+0.6%-1.2%+9.0%
Q3 2023-10.9%-11.5%-3.7%
Q2 2023-9.8%-10.5%-16.9%
Q1 2023-1.2%-0.3%-6.6%
Q4 2022+7.1%+8.0%+5.5%
Q3 2022-18.3%-16.3%-12.0%
Q2 2022-4.8%-3.2%-13.6%
Q1 2022-8.3%-11.7%-17.7%
Q4 2021-6.9%-0.3%+3.2%
Q3 2021-0.4%-1.2%-6.4%
Q2 2021+2.0%+4.2%+5.8%
Q1 2021+7.5%+10.0%+4.8%
Q4 2020-3.7%-5.3%-4.0%
Q3 2020-6.0%-7.5%+0.1%
Q2 2020+0.3%-0.6%+1.0%
Q1 2020+3.2%-1.6%+1.1%
Q4 2019-5.5%-2.7%-12.0%
Q3 2019+3.0%+6.8%+8.4%
Q2 2019+10.8%+9.7%+11.7%
Q1 2019-0.3%-1.2%-4.7%
Q4 2018-0.0%+0.8%+2.9%
Q3 2018-6.0%-6.1%-0.7%
Q2 2018-8.5%-8.2%-8.6%
Q1 2018-5.6%-5.8%+0.3%
Q4 2017+4.1%+0.4%+6.3%
Q3 2017-9.4%-10.7%-4.6%
Q2 2017+0.4%-0.6%-3.5%
Q1 2017+11.6%+12.0%+16.5%
Q4 2016-6.8%-6.6%-3.9%
Q3 2016-19.5%-17.8%-25.8%
Q2 2016+7.4%+7.5%+7.7%
Q1 2016+0.9%
Q4 2015+5.7%
Q3 2015+0.7%
Q2 2015+0.7%
Q1 2015-1.8%
Q4 2014+7.5%
Q3 2014+10.9%
Q2 2014+9.4%
Q1 2014+0.7%
Q4 2013+1.0%
Q3 2013-9.3%
Q2 2013+2.3%
Q1 2013-22.8%
Q4 2012-7.1%
Q3 2012-0.3%
Q2 2012+4.5%
Q4 2011-1.6%
Q1 2012+11.6%
Q3 2011-5.9%
Q2 2011-3.5%
Q4 2010+0.5%
Q1 2010+0.5%
Q1 2011-2.1%
Q4 2008-1.7%
Q1 2009-1.7%
Q3 2010+1.3%
Q3 2009+1.3%
Q2 2009+1.3%
Q2 2010+1.3%
Q4 2009+1.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro